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Abstract: In this paper, we review serological and molecular based methods to identify HIV
infection recency. The accurate identification of recent HIV infection continues to be an important
research area and has implications for HIV prevention and treatment interventions. Longitudinal
cohorts that follow HIV negative individuals over time are the current gold standard approach,
but they are logistically challenging, time consuming and an expensive enterprise. Methods that
utilize cross-sectional testing and biomarker information have become an affordable alternative to
the longitudinal approach. These methods use well-characterized biological makers to differentiate
between recent and established HIV infections. However, recent results have identified a number
of limitations in serological based assays that are sensitive to the variability in immune responses
modulated by HIV subtypes, viral load and antiretroviral therapy. Molecular methods that
explore the dynamics between the timing of infection and viral evolution are now emerging as a
promising approach. The combination of serological and molecular methods may provide a good
solution to identify recent HIV infection in cross-sectional data. As part of this review, we present
the advantages and limitations of serological and molecular based methods and their potential
complementary role for the identification of HIV infection recency.
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1. Introduction
Identification of HIV infection recency is crucial for the accurate estimation of HIV incidence,
the monitoring of HIV spread [1–3], the understanding of HIV transmission dynamics [4–7] and
the evaluation of prevention strategies [8]. The current “gold-standard” approach to identify
the recency of infection involves the longitudinal follow-up and repeated testing of uninfected
individuals [9–11]. However, implementation of this approach is logistically challenging, time
consuming and expensive [8].
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Methods that utilize cross-sectional testing have become an affordable alternative to the
longitudinal cohort approach [12]. These methods rely on previously characterized biomarkers of
recent infection [13–15]. Serology assays like Calypte Incidence Assay (BED) and Limiting Antigen
Assay (LAg) classify recent infections based on markers of the host immune response to HIV, such as
antibody levels, avidity, isotype and proportion [13–16]. These assays are generally cheaper, quicker
and easier to implement at the population level than the longitudinal cohort approach [17]. However,
recent results show that there are limitations in these assays as they are sensitive to variation in
immune responses that are associated with different HIV subtypes, viral load levels and antiretroviral
therapy (ART), among others.
Genomics-based assays and molecular methods that explore the dynamics between the timing
of infection and viral evolution are now emerging as a promising approach [18,19]. These methods
are based on the approximately linear genetic diversification of HIV over time [18–22] and make it
possible to differentiate recent from established HIV infections [12,13,23–27]. In this manuscript, we
specifically outline some of the recent advances in serology-based assays. We then examine a number
of emerging molecular approaches. Finally, we discuss how serology and molecular based methods
can be used together to estimate recent HIV infection from cross-sectional data.
2. Early Dynamics of HIV Infection
HIV-1 RNA viral load is detectable within days after infection. This, coupled with the absence
of HIV-1 antibodies during the early stages of infection, is a powerful marker for the identification
of acutely infected individuals [28]. For this reason, it is possible to identify acute HIV infection
by a combination of a negative HIV-1 antibody test and a positive viral load test (Figure 1) [28,29].
However, it is logistically difficult and expensive to identify acute HIV infections. This is because
the acute phase of infection is very short (typically 2–4 weeks) [28–30]. In order to identify acute
infections, one needs to follow a sero-negative cohort, which is repeatedly tested on a weekly basis
until sero-converters are identified. On the other hand, recent HIV infection is considered to last
between six and twelve months after infection [31]. This phase is the period when viral load set-point
is established and antibody responses increase. Furthermore, HIV genetic diversity increases over
time during this period (Figure 1).
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Figure 1. Markers of HIV recency: HIV-1 RNA load (A); antibody response to HIV-1 (B); and HIV-1
diversity (C). Heterogeneity of presented markers among HIV-infected individuals is highlighted by
polygons (instead of single curves): red for HIV-1 RNA, yellow for cumulative anti-HIV antibodies,
and blu for vi us diversity. Time 0 indicates tim of HIV tran mission. The nd of HIV recency
period corresponds to approximately 12 months after HIV transmission. EIA: Enzyme immunoassay
test for anti-HIV antibodies; WB: Western Blot.
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3. Serological Tests of Recent HIV Infection
Several types of serological assays have recently been developed [14,17,23,24,32] and new
biomarkers continue to be found [20]. These assays can differentiate between recently acquired
and long-term infections based on (i) the increase in antibody titers [33]; (ii) the increase in the
proportion of HIV-1 specific IgG antibodies [34]; (iii) the increase of antibody avidity [27,35]; and
(iv) a combination of these markers [36]. HIV-infected individuals are classified as either recently
or long-term infected if they fall above or below a well-defined threshold [26,37]. Serological assays
have been reviewed extensively elsewhere [14,16,17,23,24]. We focus on describing the strengths and
limitations of seven recently developed methods.
3.1. Less Sensitive Enzyme Immunoassays (LS-EIA)
The Less Sensitive Enzyme Immunoassays (LS-EIA), also known as the “detuned assay”, was
one of the first serological assays to identify HIV infection recency [38]. This assay is based on the
gradual increase in HIV-1 antibodies over time after sero-conversion. The underlying assumption is
that recently infected individuals will have lower levels of HIV-1 antibodies compared to those with
established infections. In this approach, specimens are serially tested with an enzyme immune-assay
(EIA) that is diluted (“detuned”). A recent infection is identified when a specimen tests positive with
a less diluted EIA but negative with a less sensitive EIA [38,39].
Commercial assays include the Abbott HAVAB (3A11 ELISA) and Avioq HIV-1 microelisa
(formally marketed as BioMerieux Vironostika HIV microelisa) [17]. The 3A11 ELISA is no longer
available commercially. These assays have been produced with antigens from subtype B, which is
the most common HIV strain circulating in the USA and Europe. A number of studies have tried
to evaluate these assays in the field with non-subtype B viruses [40,41]. However, non-B subtypes
produced antibodies with reduced binding affinities, leading to an increase in the false-recency
rate [42]. The LS-EIA assays are a potentially cost-effective and quick method to implement.
However, they have to be adapted to different subtypes and evaluated on a larger scale across various
geographical regions.
3.2. Proportion of HIV-1 Specific IgG Antibodies
Another frequently used serological assay is the BED capture enzyme immunoassay. This assay
is commercialized as BED-CEIA by Calypte Biomedical, United States [34]. The BED assay estimates
the proportion of HIV-1 specific IgG to the total IgG. Recent HIV infection is identified when the
HIV specific IgG is lower than the total IgG. The assay uses peptides from immunodominant regions
of gp41 glycoprotein of three different HIV-1 strains. These include (i) subtype B; (ii) circulating
recombinant form (CRF_01AE); and (iii) subtype D. The use of three different strains allows the
detection of recently infected individuals with different HIV-1 subtypes [34,43].
False-recent HIV infections are more likely to be identified in chronically infected individuals
(i.e., individuals in the late stage of HIV infection, elite controllers or individuals on
ART) [14,26,44,45]. The performance of the BED assay can be improved by adding covariate
information from clinical data or by adjusting for the false-recency rate. Its accuracy has also been
found to vary by geography [46,47] and HIV-1 subtypes [48–51].
3.3. Antibody Avidity Assays
Another approach for identifying recent HIV infections is to investigate the quality of the
antibody response. This can be done by measuring its avidity or strength of antibody-antigen binding.
The Limiting Avidity assay (LAg) was the first assay to become commercially available to measure
avidity. LAg measures the antibody binding to low concentrations of a multi-subtype peptides
derived from an immunodominant region of gp41 [27,52]. In this assay, specimens are incubated with
and without a chaotropic agent that disrupts antibody-antigen interactions. Antibodies normally
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become resistant to disruption over the course of the HIV infection. Those with low ratio avidity are
indicative of recent HIV infection [53].
Avidity assays are normally more sensitive than the BED or detuned assays [52,53].
Nevertheless, some studies have shown that this assay can be affected by other pathogens, such as
Mycobacterium Tuberculosis (TB). In addition, the assay misclassifies samples from individuals on ART
with low viral load, and in people infected with HIV-1 subtypes D [48].
3.4. Anti-p24 IgG3
IgG3 is one of the second predominant subclasses in the antibody response towards HIV [54,55].
IgG3 isotypes to p24 antigen are present in early infection and then decline. This makes IgG3 an
attractive biomarker for the identification of recent HIV infections [55–57], since high IgG3 levels are
associated with a high HIV-1 viral load [58]. The HIV-1 Bio-Plex assay is one method that specifically
measures the p24-specific IgG3 responses [59]. Although IgG3 has been observed to decline over
time, about one-third of individuals exhibit relatively high IgG3 levels in the late stage of HIV-1
infection [59].
3.5. Inno-LIA HIV Adaptation
The Inno-LIA HIV-1/2 assay measures the increase in antibody-antigen reactivity following the
seroconversion event [60]. The assay was first designed for the confirmation of an HIV diagnosis,
and is similar to a western blot test [60]. The emergence of antibodies to various HIV-1 proteins at
different time points after seroconversion is used to characterise the recency of infection [16,61]. The
Inno-LIA assay detects antibodies to recombinant peptides of HIV-1 (p17, p24, p31, gp41 and gp120)
and HIV-2 (gp36 and gp105). The intensity of the antibody-antigen bands is scored [61] and used to
determine the recency of infection [16,17].
The Inno-LIA assay is advantageous because it can be used to confirm both an HIV diagnoses
and a recent HIV infection. This assay can therefore significantly reduce costs. However, it can only
detect a recent HIV infection within 36 to 67 days of the seroconversion date. The assay has not been
evaluated in elite controllers, individuals receiving antiretroviral therapy and in individuals with a
late stage of disease or AIDS [61].
3.6. Challenges Associated with the Application of Serological Assays in Cross-Sectional Data
There are limitations to the application of serological assays to determine recent HIV infection.
Use of ART and low CD4+ cell counts can increase the false-recency rates. Low CD4+ cell counts are
associated with low antibody responses (titers, proportion and avidity) [29]. Decreased antibody
response is also associated with a low viral load level and a compromised immune function,
which leads to the misclassification of long-term HIV survivors (i.e., elite controllers or patients
successfully responding to ART) as recently infected [61–63]. Co-infections also present additional
challenges [16,24,46,48,64,65]. Lastly, false-recency rates have been shown to vary across HIV-1 strains
and geographical regions [46,66].
The World Health Organization has established a Technical HIV Incidence Assay Working
Group (HIVIWG) to provide guidelines and recommendations on how to use serological assays.
These include adjusting certain parameters, such as the false-recency rate for a given geographical
region [37,67]. In addition, there is a need to document the use of ART, viral load levels and CD4+
cell counts. However, detailed information may not always be obtained from surveillance programs
in resource-limited settings. The HIVIWG hope that a new generation of avidity assays can overcome
these challenges [36,68].
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Table 1. Comparison of the molecular based approaches for determination of HIV recency.
Assay or Test
Type or Recent
Infection
Algorithm
Brief Summary of the Assay or Test Strengths Limitations References
High Resolution
Melting Assay
Measures diversity of generated
amplicons by using melting
temperature of DNA duplexes.
‚ Relatively inexpensive
‚ Does not require viral genotyping
‚ PCR may be poor scalable in rural and resource
constrained settings.
‚ Sensitive to indels that are common in HIV.
‚ Unable to distinguish between infections caused
by single or multiple viral strains.
[69–71]
Counting
Sequence
Ambiguities
Ambiguous bases in the viral sequence
indicate heterogeneous virus
population. The number of ambiguous
bases is small in recently infected
individuals and increased overtime.
‚ Can be cost effective if routine drug
resistance testing is a part of clinical care
‚ Not cost effective in resource limited settings.
‚ Can underestimate ambiguous positions.
‚ The impact of ART exposure is unknown and
could be a serious concern.
‚ The number of ambiguous positions in the late
stage of HIV infection could be reduced, which
may lead to misclassifications.
[18,19,72,73]
Naïve Bayes
Classifier (NBC)
Utilized the frequency of ambiguous
sites together with CD4+ cell counts
and any concurrent AIDS defining
illness. The Bayesian probability
framework estimates the probability of
a patient to be in one of four stages of
HIV infection.
‚ High positive predictive value
‚ Can be retrospectively fitted to available
genotypic and clinical data
‚ Requires substantial validation.
‚ The method has been applied only once in HIV-1
subtype B settings.
[74]
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Table 1. Cont
.
Assay or Test
Type or Recent
Infection
Algorithm
Brief Summary of the Assay or Test Strengths Limitations References
Hamming
Distance (HD)
The HD is a number that denotes the
difference between two sequences of
equal length. It is the simplest
measure of HIV diversity. HD can
measure the number of nucleotide
differences between a pair of virus
sequences. If applied to viral
quasispecies from the host, HD can
estimate the stage of HIV infection.
‚ High sensitivity and specificity
‚ Simplicity
‚ The HD approach has not been validated in
long-term non-progressors, rapid progressors, and
among ART-experienced individuals.
‚ It is unclear how indels and viral recombination
can affect the HD estimates.
‚ Requires viral quasispecies. May have limited use
in the resource-constrained settings.
[21,75]
Sequence
Clustering Based
Diversity Measure
(SCBD)
Intra-cluster genetic diversity is used
as the measure of time since infection.
Inter-cluster diversity is used to
determine whether there were
multiple founder strains and the dot
matrix incorporates information on
indels and recombination.
‚ Good accuracy
‚ High sensitivity and specificity
‚ It is unclear how indels and viral recombination
can affect the estimates.
‚ Is time consuming and expensive. [76]
Multi-Assay
Algorithms
(MMA)
Results of serology-based test of
recent infection combined with:
Clinical data (e.g., CD4+ cell counts,
HIV-1 RNA load, ART status)
Measure of HIV diversity
Combination of Assays can be
optimized to increase accuracy.
‚ Provides more accurate estimate of the
HIV recency
‚ Reduces false recency
‚ Not validated across HIV-1 subtypes and
different populations.
‚ Requires clinical data (e.g., CD4+ cell counts, viral
load count).
‚ Might be problematic logistically in
resource-limited settings.
[69,77,78]
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4. Molecular Tests of Recent HIV Infection
Most HIV infections are caused by a single transmission (i.e., founder) virus, which results in
an initial homogenous viral population that will diversify over time [79–82]. Upon transmission, the
virus is able to diversify rapidly within the host due to immune response and the fact that HIV-1
Reverse Transcriptase enzyme is error prone. Virus genetic diversity increases in an approximately
linear fashion for several years after infection, reaches a plateau, and declines in the late stage of
infection [18]. Virus diversification in early HIV infection provides a strong rationale for identifying
recent HIV infection [19,69,83,84]. Some methods, such as the high resolution melting assay (HMA),
are able to estimate HIV recency without the use of a viral genotype [70]. However, the majority of
molecular methods utilize viral sequences. Molecular methods that use sequences were developed
for population [18,19,72] and single-genome or clonal sequencing [85]. Table 1 provides a summary of
the strengths and limitations of molecular based methods. In this review, we describe five methods.
4.1. High Resolution Melting Assay
The high resolution-melting (HMA) assay is one of the simplest molecular methods. The assay
uses the melting temperature of the DNA duplexes from amplicons. Multiple regions across the
HIV-1 genome including gag, pol and env can be used [69–71] without the need to sequence them.
HMA provides a single numeric score that reflects the level of diversity in the amplified region,
which increases linearly over the course of the HIV infection [69]. There is concordance between
the HMA score and viral diversity. This was obtained by next generation sequencing (NGS) and
Shannon entropy analysis [86,87].
This assay is a relatively inexpensive technology that can be implemented in resource-limited
settings that do not have access to sequencing infrastructure. For example, HMA has been
successfully used in clinical trials in Uganda [88]. However, it has been shown to have limitations.
For example, the assay is sensitive to insertions and deletions [89], which are common features of the
HIV genome. Another limitation is its inability to distinguish between infections caused by single and
multiple HIV strains. The HMA assay can be adapted to many HIV strains and could complement
serological assays in resource-limited settings [90].
4.2. Sequence Ambiguities as a Marker of Recent HIV Infection
This approach is based on counting ambiguous nucleotide positions produced during
population Sanger sequencing. Multiple nucleotides at the same position indicate that PCR
amplification was performed from multiple templates and that the patient harbors heterogeneous
viruses. The number of ambiguous positions increases as the viral population diversity grows over
time [18,73]. For example, a linear increase in viral diversity within HIV-1 pol is associated with an
increase of 0.2% ambiguous nucleotides per year [18]. A significant difference in the frequency of
ambiguous sites has been observed among individuals with recent and established HIV infections in
both HIV-1 subtype B and non-subtype B infections [18,73].
A number of different threshold values for the ambiguity index have been suggested.
Anderson et al. [73] found that a threshold of 0.47% performed the best in discriminating recent
(ď1 year) from established HIV infections. In that manuscript, the threshold of 0.47% returned
a sensitivity of 74.5% and specificity of 87.2%. Brooks et al. [19] compared BED classification
(ď6 months) with the ambiguity index using a threshold of 0.45%, which provided a sensitivity and
specificity of 82.7% and 78.8%, respectively. They also found that varying the base-calling thresholds
had little effect on the sensitivity and specificity. However, the two previously mentioned studies
used different base calling strategies, PCR and sequencing methodologies, which makes it difficult to
compare their results. One further limitation of the Brooks et al. paper is that the BED assay was used
as the “gold standard” to identify recent HIV infections. As described earlier, this assay has been
shown to have a high false-recency rate [14,26,44,45].
5514
Viruses 2015, 7, 5508–5524
A limitation of this method is that it normally underestimates the number of ambiguous
positions during Sanger sequencing [85]. Another limitation is the non-homogenous selective
pressure of the immune system on HIV genetic regions, which makes it difficult to choose one unique
threshold. Other limitations include the unknown impact of ART, the effect of low HIV-1 RNA in
viremic/elite controllers and the reduced number of ambiguous positions in the late stage of HIV
infection [91,92]. Lastly, HIV infection with multiple viruses can attenuate accuracy.
4.3. Naïve Bayes Classifiers
The naïve Bayes classifier is based on the observation that viral diversity increases in an
approximately linear fashion over the course of HIV infection [80,91]. This method makes use
of available clinical markers such as CD4+ cell counts over the course of HIV infection and any
concurrent AIDS associated diagnosis [93]. Individuals are classified into one of four different stages
of HIV infection. The first stage limits HIV infection to within one year, with two intermediate
stages that include chronically infected individuals, and a fourth stage which corresponds to AIDS
(as defined by a CD4+ < 200 copies/mL). A standard Bayesian model can be fitted to estimate the
probability of an individual being in one of the four stages conditional on the frequency of ambiguous
sites in the HIV-1 pol gene, the CD4+ cell count and a concurrent AIDS diagnosis. The naïve Bayes
classifier was designed to have a high positive predictive value for identifying true recent HIV
infections [74].
This method was successfully used to estimate the proportion of individuals at different stages of
HIV infection in a large sequence cohort of HIV-1 subtype B infected men who have sex with men in
the Detroit metropolitan area [74]. The study utilized HIV-1 pol sequences available through a routine
drug resistance-screening program coupled with available clinical data to estimate prevalence,
incidence and timing of HIV transmission. The authors found that individuals were eight times as
infectious during the first year of HIV infection as compared with individuals who had established
infections. They also found that 42% to 46% of the HIV transmissions came from individuals who
were recently infected. This method has a great potential to understand how HIV recent infection can
drive different HIV epidemics. However, it needs to be applied and evaluated in different geographic
regions and with different HIV-1 strains.
4.4. Hamming Distances
The Hamming distance (HD) is a number that denotes the difference between two binary strings
of equal length, i.e., the number of positions at which the corresponding symbols are different. In
relation to HIV diversity, HD can be used to measure the number of nucleotide differences between
pairs of sequences. When applied to viral quasispecies, HD can be used to estimate the stage of HIV
infection [21,75]. The HD of recent HIV infections, caused by a single founder virus, does not overlap
with the HD from established HIV infections. However, HDs of infections resulting from multiple
founder viruses can overlap, resulting in a misclassification as an established infection.
Park et al. devised a binary classification (recent vs. established infection) based on the tail
characteristics of the Hamming distance distribution of HIV-1 env sequences [75]. An HD value that
divides the lower 10% (Q10) of the HD frequency distribution from the upper 90% was shown to be
able to distinguish a recent from an established HIV infection. The Q10 statistic was lower in recent
HIV infections compared to chronic infections, and was shown to distinguish whether infections
originated from a single or multiple founder strains. The authors also demonstrated a high sensitivity
(97%) and specificity (100%) when applying the Q10 statistic.
This approach has recently been applied to high throughput pyrosequencing data and has the
potential to be cost-effective for routine surveillance [94]. The test is yet to be validated in long-term
non-progressors, rapid progressors and among ART-experienced patients. A further limitation is
the potential impact of indels and recombination, particularly when using variable regions across
the HIV-1 genome, such as env. The HD approach also does not take into account the nature of the
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evolutionary events. The assay relies on availability of viral quasispecies and might not be widely
used in resource-limited settings without routine HIV genotyping infrastructure.
4.5. Sequence Clustering Based Diversity Measure
A sequence clustering based measure (SCBD) of HIV diversity has been proposed by
Xia et al. [76]. The SCBD method determines HIV infection recency by using two principles. The
first principle involves intra-patient clustering, which is defined as the closeness of viral quasispecies
within an individual’s sample. An increase in intra-patient HIV diversity is correlated with the time
since infection [76]. The second principle uses inter-patient HIV diversity, which is a measure of the
presence of multiple founder viruses within an individual. The algorithm of the SCBD method first
classifies an infection as recent if there is a low intra-patient diversity. If there is high inter-patient
diversity, then the SCBD method will classify the sample as originating from a long-term infected
individual. The purpose of the method is to reduce the misclassification of recent infections by using
the inter-patient clustering measure.
In order to minimize the impact of indels on calculated diversity, the authors used a pairwise dot
matrix alignment, which accounts for the nature of evolutionary events when calculating pairwise
diversity. Xia et al. [76] proposed a SCBD cut-off of 1.0% based on the known evolutionary rate of the
env gene [91]. The assay was tested on a dataset containing 398 incident and 163 chronic infection
cases. It achieved an overall accuracy of 99.3%, with a sensitivity and specificity of 99.5% and 98.8%,
respectively. The method overcomes the limitations of using only intra-patient diversity, since these
do not account for the impact of indels and recombination on calculated diversity measures. The
application of this method could be limited as the generation of HIV quasispecies are costly and
labor intensive.
5. Multi-Assay Algorithms
HIV-1 subtype variability, heterogeneity of host immune responses and exposure to ART could
impact the sensitivity and specificity of EIA assays. The combined use of different assays [36,67]
could improve the accuracy of these methods to identify recent HIV infection. Recent HIV infection
testing algorithms (RITA) can complement EIA assays by using clinical data (CD4+ cell counts, viral
load data and ART use) to improve accuracy [12,68,77,81]. This approach helps to reduce false-recent
rates caused by the natural or ART induced viral suppression [36,45]. Testing for traces of ART in the
specimens could further reduce the misclassification of recent HIV infection [36,77,95].
Laeyendecker et al. [77] used a multi-assay algorithm (MAA) to test specimens with the BED
assay. This procedure was then followed by viral load testing with a Bio-Rad avidity assay. Specimens
with undetectable viral load were further tested for the presence of ART, improving the method to
identify established cases of HIV infection [77].
An alternative MAA approach, which does not require viral load data, uses a Bio-Rad avidity
(cut-off of 40% Avidity Index). It then confirms HIV infection recency using a LAg cut-off of
normalised optical density at 2.8 [78]. This approach has a low false-recency rate, but the mean
duration of HIV recency was reduced to 119 days and required larger sample sizes [78]. This MAA
can be applied to dried blood spots making it an attractive method for resource-limited settings.
Another MAA begins by using CD4+ cell count information to exclude immuno-compromised
individuals with AIDS [36,78]. Samples identified as recent HIV infections with the Bio-Rad avidity
index assay were confirmed by the LAg assay. Recent infections classified by the LAg assay were then
tested for viral load. Only specimens with detectable viral load were classified as recent infections
regardless of ART exposure [78]. The mean duration of recency was identified as 146 days. One
limitation is that a strong laboratory support is required for the implementation of MAAs that
includes testing for viral load and ART exposure [78]. This support may not be fully available in
resource-limited settings.
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Requirement of fresh and whole blood CD4+ cell count may limit the applicability of MAAs. The
additional resources required by the MAAs may not be justifiable for a marginal gain in precision.
Novel MAA approaches have the potential to eliminate the need for CD4+ cell count and/or viral
load information. One such approach, based on HIV diversity (HMA assay), was proposed by
Cousins et al. [69]. This MAA tested specimens with BED and Bio-Rad avidity assays, and applied
the HMA assay as a confirmatory test. The results were comparable to the MAA that included CD4+
cell count [69].
Well-designed and optimized MAAs will be able to improve the identification of HIV infection
recency. However, this approach still needs to be evaluated across different HIV-1 subtypes and
standardized [26].
6. Discussion
In this paper, we have provided a review of serological and molecular based methods to
determine HIV infection recency. These methods provide a promising alternative to the standard
longitudinal cohort approach, which is expensive, time consuming and difficult to implement.
Methods that utilize cross-sectional biomarker information are likely to be more affordable and easier
to implement in larger cohorts. Research has shown that serological based assays can detect recent
HIV infections with a good accuracy at a substantially lower cost than longitudinal testing [14].
The new generation of antibodies avidity assays, for example, the LAg assay, has shown improved
accuracy [68]. However, serological based assays are also sensitive to the variability in immune
responses modulated by HIV clades, viral load levels and ART. Recent reviews of the serological
based assays have concluded that there is an urgent need to develop new biomarkers while improving
existing ones [20,96].
Molecular methods that use viral diversity have emerged as a novel and promising area of
investigation and could complement existing serological based assays. Viral-based assays have a
significantly lower misclassification rate than their serological counterparts, but are more expensive
and difficult to implement [69,90,97]. However, recent advances in sequencing technology and the
increasing availability of sequence data may enable the implementation of these assays in the field.
The current assays are promising but require further validation and standardization for different
settings, especially in sub-Saharan Africa where there are multiple circulating HIV subtypes and high
prevalence. A Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA)
has recently been established with the support from the Bill and Melinda Gates Foundation (BMGF)
(Seattle, WA, USA). The aim of this consortium is to create a specimen repository to allow for an
independent evaluation of assays [26] and algorithms.
Phylogenetic analysis has also emerged as a new tool. Combined with epidemiological
and clinical data, phylogenies can be used to identify recently HIV infected individuals and to
determine their contribution to the spread of local epidemics [74,98,99]. Volz et al. studied the
dynamics of HIV transmission in Detroit and confirmed that a disproportionate fraction of viral
transmissions originated from the very early stages of HIV infection [74]. They concluded that HIV
transmissions could be reduced if recently infected individuals were identified and started on ART
immediately [100].
It is likely that an optimal algorithm for the identification of HIV infection recency will be
based on a combination of serological and molecular based assays. Low cost HIV diversity assays,
such as HMA or the use of sequences already generated for drug resistance surveillance, could
be implemented across resource-limited settings. Advances in high throughput sequencing could
further improve affordability and scalability. The integration of clinical or epidemiological data
with this approach, if available, could further improve the performance of MAAs. However,
cost-effective studies will be needed to guide the implementation of MAAs across resource-limited
settings. Implementing single genome amplification and NGS will be of further value in terms of
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addressing specific research questions related to viral linkage, sexual networks and the identification
of sub-epidemics.
7. Conclusions
HIV infection recency can be estimated by a set of contemporary serological and molecular
methods based using cross-sectional sampling. We expect that the methods reviewed here will further
advance in the near future with the recently created WHO and BMGF consortiums. In addition,
the usage of phylogenetic methods that take into account recent HIV infection will provide a better
understanding of the transmission dynamics of HIV in sub-epidemics. These methods may replace
longitudinal cohorts that are commonly used to evaluate HIV prevention and treatment interventions.
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